Faculty & Research
Faculty & research are integral components of BME. With a strong focus on research, BME is located in the heart of Canada’s largest health-care research hub. Our graduate students receive their training from 14 departments at U of T, 10 partner hospitals, and 7 research institutes & commercialization centres.
At BME, our cross-disciplinary approach in biomedical and clinical engineering enables our researchers to cover a diverse set of topics. Find out what our research publication are saying about our research focus.
Quick Navigation
Faculty directory
Core Faculty
We have 30+ core faculty members that span across cell & tissue engineering, clinical engineering, and molecular engineering disciplines.
Cross-Appointed Faculty
BME currently hosts cross-appointed faculty members across more than 30 academic units, partner hospitals, research institutes, and commercialization centres.
Emeriti
Learn about some of our retired faculty members
Research streams
Clinical
BME’s clinical engineers design technologies, devices and strategies for people with chronic disease, traumatic injury, disabilities and mobility limitations to help them integrate more fully with their environment.
Cell & Tissue
Research that has the potential to change how we think about disease and aging is happening at BME. Regenerative medicine uses stem cells and biomaterials to repair, replace or regenerate damaged tissue, organ structures and function.
Molecular
BME researchers are advancing disease detection, customizing drug delivery and improving health-care outcomes with faster and more precise technologies and systems.
Latest news
Quagga mussel protein offers new source of inspiration for medical-grade adhesives that work in wet conditions
Researchers at the University of Toronto have identified a protein from the quagga mussel that can stick to surfaces underwater, even though it lacks a chemical feature long thought to be essential for this kind of adhesion. The protein, called Dbfp7, is the first freshwater mussel adhesive protein to be functionally characterized.
Mining the dark transcriptome: U of T Engineering researchers create the first potential drug molecules from long noncoding RNA
A team from U of T Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell — a new approach to drug discovery that has already yielded some promising anti-inflammatory molecules.
MRI technique enables long-term tracking of transplanted stem cell–derived heart cells
Dr. Keyu Zhuang (left, currently a Specially Appointed Research Fellow at Clinical Cardiovascular Research Institute at Shanghai University School of Medicine ) and Professor Hai-Ling Margaret Cheng (right) at the Institute of Biomedical Engineering at the University of Toronto have developed an MRI method to track transplanted stem-cell-derived heart cells over time, enabling scientists to monitor their survival and improve therapies for heart damage such as that caused by heart attacks (Photo: KITE Studio, Tim Fraser).
Faculty startups
The following list highlights some of the startup companies that have been launched by these forward-thinking faculty members, demonstrating their commitment to translating academic knowledge into real-world applications and making a significant impact on the biomedical industry.
| Faculty Member | Commercialization Venture | Focus | Location |
|---|---|---|---|
| Jan Andrysek | LegWorks | Prosthetic Knee Joint | San Francisco |
| John E. Davies | Tissue Regenerative Therapeutics Inc. | Mesenchymal Stem Cells | Toronto |
| Milos Popovic | MyndTech Inc. | Medical Tech Company | Mississauga |
| Milica Radisic | Tara Biosystems | Cardiac Drug Discovery | New York |
| Jonathan Rocheleau | QuantM3 | Microfluidics Technology Diabetes Treatment | Toronto |
| Paul Santerre | Interface Biologics | Drug Delivery and other technologies | Toronto |
| Paul Santerre and Eli Sone | Cohesys Inc | Bone Tape to replace plate and screws in craniofacial repair; Angel investment | Toronto |
| Paul Santerre | Ripple Therapeutics | Non-polymeric anti-inflammatory drug delivery systems for ophthalmology; venture invested | Toronto |
| Molly Shoichet | AmacaThera | Injectable hydrogel platform technology | Toronto |
| Aaron Wheeler | Miroculus (formerly Kappex) | Digital Microfluidics Platform | Toronto |